Program
Bupropion
Also written as “bupropion hydrochloride”, “Extended-release Bupropion Hydrochloride” and “Extended-release bupropion hydrochloride”.
Its studies are mostly in Smoking Cessation · Depressive Disorder, Major · Depressive Disorder · Seasonal Affective Disorder · Obesity, led by 6 companies.
Drug pageBupropion: every studyMany companies study it; this page follows only the 19 they lead. All 217 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 80 open or running | phase 3since Sep 24, 2002 | Sep 24, 2002 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Rose Research Centerits history only | 20 open or running | phase 3since May 11, 2020 | May 11, 2020 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since Oct 2, 2015 | Oct 2, 2015 | none ahead |
| Novartis | 10 open or running | phase 1since Apr 16, 2009 | Apr 16, 2009 | none ahead |
| Takedaits history only | 10 open or running | phase 4since Nov 24, 2015 | Nov 24, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2009First study: phase 1 study in HealthyFirst studyNCT00883155 · 36 enrolled
TargetBeta
“Dopamine transporter inhibitor; Dopamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| dexmethylphenidaterule | cingulate-therapeutics | phase 4 | 14 |
| Amphetaminerule | Tris Pharma | phase 4 | 8 |
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00883155Healthy | 1 | Completed | Oct 1998 | 36 |
How it is read
Names in the registry
- “Bupropion”, 7 entries
- “bupropion hydrochloride”, 3 entries
- “Extended-release Bupropion Hydrochloride”, 2 entries
- “Extended-release bupropion hydrochloride”, 2 entries
- “Bupropion HCl”, 2 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 5 studies
- Depressive Disorder, Major, 4 studies
- Depressive Disorder, 2 studies
- Seasonal Affective Disorder, 2 studies
- Obesity, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.